1614-12-6
基本信息
1-氨基苯并三氮唑
1-苯并三唑胺
1-BENZOTRIAZOLAMINE
1H-1,2,3-BENZOTRIAZOL-1-YLAMINE
ABT
RARECHEM AQ NN 0550
TIMTEC-BB SBB004208
1-Benzotriazolylamine
1H-Benzotriazol-1-amine
1H-Benzotriazole,1-amino-
Benzotriazol-1-ylamine
1-Aminobenzotriazole 97%
ABT, 1-Benzotriazoleamine
1-Benzotriazolamine, ABT
1-(Thiophen-2-yl)-4-[(2-aminoethyl)amino]-1-butanone
4-[(2-Aminoethyl)amino]-1-(2-thienyl)butan-1-one
1-Amino-1H-benzotriazole
物理化学性质
| 熔点 | 81-84 °C(lit.) |
| 沸点 | 237.24°C (rough estimate) |
| 密度 | 1.2769 (rough estimate) |
| RTECS号 | DM1235000 |
| 折射率 | 1.7000 (estimate) |
| 储存条件 | Keep in dark place,Sealed in dry,Room Temperature |
| 溶解度 | 可溶于DMSO（高达30mg/ml） |
| 酸度系数(pKa) | 2.09±0.30(Predicted) |
| 形态 | 结晶粉末 |
| 颜色 | 黄色至米色或浅棕色 |
| 水溶解性 | 微溶 |
| BRN | 607843 |
| 稳定性 | 可在-20°C下的DMSO溶液保存长达1个月。 |
| CAS 数据库 | 1614-12-6(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P261-P264-P271-P280-P302+P352-P305+P351+P338 |
| 危险品标志 | Xi |
| 危险类别码 | R36/37/38 |
| 安全说明 | S26-S36-S37/39 |
| WGK Germany | 3 |
| Hazard Note | Irritant |
| 海关编码 | 29349990 |
知名试剂公司产品信息
1-Aminobenzotriazole,>98.0%(GC)(1614-12-6) TCI Shanghai
1-氨基苯并三唑价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/11 | XW161412602 | 1-氨基苯并三唑 | 1614-12-6 | 1G | 282元 |
| 2024/11/08 | 34864 | 1-氨基苯并三唑 1-Aminobenzotriazole, 98%, Thermo Scientific Chemicals | 1614-12-6 | 100mg | 1512元 |
| 2024/11/08 | 34864 | 1-氨基苯并三唑 1-Aminobenzotriazole, 98%, Thermo Scientific Chemicals | 1614-12-6 | 250mg | 2823元 |
常见问题列表
| Target | Value |
|
P450
() | |
|
NAT
() |
1-Aminobenzotriazole (ABT) alone significantly increases the expression levels of CYP2B6 in two different hepatocytes (7.3- and 10.8-fold, respectively). Upon co-treatment with 1-Aminobenzotriazole, the induction of CYP2B6 expression by CITCO or rifampin is potentiated: 12.6- and 4.0-fold for CITCO as well as 3.9- and 2.5-fold for rifampin. 1-Aminobenzotriazole has a greater potentiation effect on CITCO than on rifampin. 1-Aminobenzotriazole alone increases the expression levels of CYP3A4 in tow different hepatocytes (by 2.0- and 3.8-fold). Upon co-treatment with 1-Aminobenzotriazole, the effects of CITCO on CYP3A4 expression levels are potentiated by 3.8- and 6.0- fold as compare to cells treated with CITCO alone. 1-Aminobenzotriazole (ABT) (1 mM) shows pronounced (~95%) inhibition of the formation of N-acetylprocainamide compare with the control without 1-Aminobenzotriazole.
Oral 1-Aminobenzotriazole (ABT) (100 mg/kg, 2 h predose) decreases the clearance of intravenous procainamide (45%) in rats, accompanied by a decreased N-acetylprocainamide-to-procainamide ratio in urine (0.74 versus 0.21) and plasma (area under the curve ratio 0.59 versus 0.11). The urinary recovery of procainamide increases from 18 to 30%, whereas the recovery of N-acetylprocainamide in urine decreases from 13.3 to 6.5% with 1-Aminobenzotriazole. Pretreatment of rats with 100 mg/kg oral 1-Aminobenzotriazole (ABT) administered 2 hours before a semisolid caloric test meal markedly delays gastric emptying. 1-Aminobenzotriazole also increases stomach weights by 2-fold.